Long-term Testosterone Beneficial in Hypogonadal Men

After stopping the injections, all but two of the participants’ sperm concentrations returned to the fertile reference range; recovery to normal values required 182days on average (Gu et al., 2009). T therapy in obese men increased hemoglobin concentrations and hematocrit but the levels remained within physiological ranges (Tables 2 and 4). T therapy in men in all three classes of obesity increased prostate volume. In fact, lower urinary tract symptoms decreased, as assessed by the IPSS scale (Tables 2 and 4). As expected, serum prostate-specific antigen increased in all men in the three classes of obesity but the increase was not deemed clinically meaningful. Eight patients were diagnosed with low-grade prostate cancer while on T treatment.

• Nebido for the treatment of male hypogonadism (testosterone deficiency) is available in over 80 countries since 2004.
• However, the FDA approved Aveed, a similar drug from Endo Pharmaceuticals, in 2014.
• TU alone was found to induce azoospermia in 96% of Chinese men (23/24, tea seed oil formulation, 500 or 1000 mg every 4 weeks) and in 57% of Caucasian men (8/14, castor oil formulation, 1000 mg every 6 weeks).
• Other preparations, testosterone enanthate and testosterone epionate, are given at 1–2-week intervals.
• The change from baseline was −30.5±0.7 kg and the percent change from baseline −23.6±0.5%.

Reductions of waist circumference (a), body weight (b), BMI (c) and weight change (d) in 411 hypogonadal men receiving long-term testosterone treatment. Trough levels of total testosterone (mean±s.e.) in 411 hypogonadal men in obesity classes I, II, and III receiving long-term testosterone treatment. Ethical guidelines as formulated by the German ‘Ärztekammer’ (the German Medical Association) for observational studies in patients receiving standard treatment were followed. After receiving an explanation regarding the nature and the purpose of the study, all subjects consented to be included in the research of their treatment protocol. “The long-term data are intriguing and the magnitude of changes came as a surprise, even to many experts who have been working with testosterone for decades,” Dr. Saad told Medscape Medical News. “The findings are more than promising, especially when it comes to obesity, for which neither medicine nor the pharmaceutical industry has found a good answer.”

Bayer to sell men’s health product Nebido™ to Grünenthal

In addition, body weight was reduced by 12.9 kg, from an average of 106.6 to 93.7 kg. Dr Saad is therapeutic area head of global medical affairs andrology at Bayer AG. These data are very intriguing, said Landon Trost, MD, head of andrology and male infertility at the Mayo Clinic in Rochester, Minnesota, who is a member of the American Urological Association guideline committee on hypogonadism. “When you restore testosterone to normal levels, behavior changes in a subtle manner. Anecdotally, men reported walking and cycling more and getting involved in sports, so they became more active than before,” said Dr Saad. At baseline, the average level of glycosylated hemoglobin (HbA1c) in the men with diabetes was about 8%, meaning that the majority of men had poor glycemic control with standard diabetic treatment, said Dr Saad.

Pellets of crystallised testosterone are implanted subcutaneously under local anaesthesia by a small incision in the anterior abdominal wall, using a trocar and cannula. Three implanted pellets (total 600 mg) give hormone replacement for about 6 months. There is an approximately 10% risk of extrusion of the pellets; infection and haemorrhage are uncommon. A tablet is placed in the small depression above the incisor tooth twice daily.

Liquid Nebido Bayer, 250 gm

Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men. Dr. Saad said that epidemiologic studies consistently suggest that testosterone deficiency are found in about 50% of men with type2 diabetes. In this context, he said, screening of diabetic men “may be justified, but in the world of diabetes treatment, testosterone deficiency is still not well known.”

• “More muscle means more calorie consumption, and this is part of the reason men lose weight on testosterone,” he said.
• The transaction is expected to close by the end of 2022, pending the satisfaction of customary closing conditions, including approval by the competition authorities.
• Coauthor L.J. Gooren reports receiving lecture honoraria from Organon, Bayer Schering Pharma, and Haider; and receiving travel grants from Bayer Schering Pharma and Takeda.
• These are “probably going to be the best long-term data we have, and there are shortcomings,” he said.
• The combination of TU with a progestogen has also been studied in Caucasian subjects (see below).

Customers who registered for the programme were provided with dynamic content recommendations based on their individual preferences and behaviour (by utilising a profiling matrix and leveraging customer insights across channels). Select at least one primary interest below to receive curated, daily newsletters designed by senior editors so you can quickly scan the latest news and analysis in your area of practice. Another “unique effect” of testosterone is the fact that it “automatically” builds muscle mass — one of the main reasons it is abused when taken in supraphysiological doses. Not surprisingly, approximately 35% of the men in both groups had type 2 diabetes. The researchers used propensity-matched 8-year data on 82 men in each group for their analysis. At the time, the registry was not supported by industry, but it was later championed by Dr Saad as a project that needed some form of financial backing because 4 to 5 years into the registry’s existence, the data were beginning to look extremely tantalizing.

Testosterone Replacement Improves Male Metabolic Syndrome

We did not collect any information on lifestyle habits or the changes thereof. Finally, we did not anticipate the marked and significant WL in this study. However, the fact that WL had not been expected validates the results as patients had not gone into the study with the intention to lose weight. It should be http://www.flourishpurefoods.com/new-study-reveals-the-impact-of-amino-acid-191-10 noted that testosterone preparations are not indicated for the treatment of obesity but for hypogonadism. We should emphasize that the increases in prostate volume noted in this study were expected as hypogonadism results in decreased prostate volume and T therapy restores prostate growth to its mature size.

In addition, the increases in prostate-specific antigen are also similar to that reported previously with T therapy.56 T therapy is always met with a number of challenges. Although this myth has been debunked,56, 57, 58, 59 the continued fear and apprehension of physicians from litigation remains a huge challenge to T therapy in men with obesity. Indeed, eight patients were diagnosed with low-grade prostate cancer in this study. This incidence rate is low compared with an untreated population of a similar age, as reported previously.56 It should be made clear that all patients were monitored closely, according to the guidelines of the European Association of Urology. Levitra(R) may also be safe and effective in lessening the symptoms of bothersome lower urinary tract age related symptoms such as urgency and frequent urination. The study investigators concluded that Levitra(R) could be developed to be used as an effective treatment of BPH/LUTS.

The US Has Prolonged The COVID-19 Public Health Emergency

Currently, phase III contraceptive efficacy trials are in progress in China using TU alone at 1000 mg every 8 weeks. The combination of TU with a progestogen has also been studied in Caucasian subjects (see below). Pharmaco-therapeutics used to treat obesity must meet several important criteria, including (a) long-term WL and weight maintenance, (b) should be well tolerated and exhibit no major safety concerns, (c) patients would adhere to the therapy and remain compliant. One most noted observation is that with nonsurgical WL interventions including pharmacotherapy, most WL occurs in the first 6 months after which there is a weight plateau, or a small degree of WL or gain when followed-up for longer term. Thus, T therapy for treatment of obesity meets the aforementioned criteria. Simply, T therapy produces WL, is well -tolerated and safe, and no weight regain, and patient compliance is very high.

Pharma Drugs Gain From Tardigrade Proteins, Says Research

Bayer has sold off the rights to Nebido (testosterone undecanoate), its injectable treatment for testosterone deficiency, to Grünenthal for approximately $503 million. Bayer Schering Pharma will use results from REPEAT as a part of their award-winning patient education programmes to help couples continue on treatment. This study is a further example of Bayer Schering’s commitment to ensure that Levitra(R) helps couples around the world; and follows on from the world-wide release of the very positive results of the Real-Life Safety and Efficacy of Vardenafil (REALISE) study(2). The REALISE study, the largest study of erectile dysfunction (ED) in the world, a PMS study covering 50 countries, 30,000 investigators and over 100,000 patients showed Levitra(R) to be efficacious and safe when used in the real-world. Testosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity.